Sickle Cell Disease Market to Witness Promising Upswing by 2034, DelveInsight Forecasts | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA

The Key Sickle Cell Disease Companies in the market include - BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, Alexion Pharmaceuticals, Takeda, CSL Behring, Fulcrum Therapeutics, Sana Biotechnology, and others .

DelveInsight's "Sickle Cell Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom.

To Know in detail about the Sickle Cell Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Sickle Cell Disease Market Forecast [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Sickle Cell Disease Market Report:

*
Among the 6MM countries the Sickle Cell Disease market size was valued ~USD 650 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In August 2025, Pfizer is reassessing its path forward after its experimental sickle cell disease therapy failed to achieve the primary endpoint in a Phase III trial. The THRIVE-131 study (NCT04935879) was testing inclacumab, a P-selectin inhibitor, in patients aged 16 and older with sickle cell disease. However, the trial did not demonstrate a significant reduction in vaso-occlusive crises (VOCs) over 48 weeks, casting uncertainty on the drug's future prospects.

*
In June 2025, Ellarity has initiated dosing of the first participant in a Phase I clinical trial of its oral drug candidate, CLY-124, for the treatment of sickle cell disease (SCD). This milestone comes after the US FDA cleared the company's investigational new drug (IND) application. The global study is designed to assess the safety, tolerability, and pharmacokinetics of the therapy, first in healthy volunteers and subsequently in patients with SCD.

*
In June 2025, The US FDA granted a special designation to Vascarta's lead candidate, VAS-101 (Vasceptor), for the treatment of sickle cell disease (SCD). This status offers key advantages, including seven years of market exclusivity upon approval and certain FDA fee exemptions. VAS-101 is a patented topical curcumin formulation utilizing Vascarta's transdermal delivery technology, developed to address the poor bioavailability and limited effectiveness of oral curcumin. Preclinical studies in animals indicate that VAS-101 may help reduce chronic pain, stabilize red blood cells, and decrease inflammation in SCD patients.

*
In May 2025, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines via base editing, announced it will share new findings from its BEACON Phase 1/2 clinical trial of BEAM-101 at the upcoming European Hematology Association 2025 Congress (EHA2025), scheduled for June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ex vivo genetically modified cell therapy being developed to treat sickle cell disease (SCD), specifically in patients experiencing severe vaso-occlusive crises (VOCs).

*
In December 2024, Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company specializing in precision genetic medicines using base editing, has unveiled new safety and efficacy findings from its BEACON Phase 1/2 trial of BEAM-101 in sickle cell disease (SCD) patients experiencing severe vaso-occlusive crises (VOCs). These results were highlighted in the press program at the 66th American Society of Hematology (ASH) Annual Meeting.

*
In November 2024, BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial-stage biopharmaceutical company focused on oncology and rare diseases, announced that an abstract featuring initial results from a Phase 1 trial of motixafortide-both as a monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization in gene therapies for sickle cell disease (SCD)-has been accepted for oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 7-10, 2024, in San Diego, California. Conducted in collaboration with Washington University School of Medicine in St. Louis, this proof-of-concept study aims to explore alternative HSC mobilization approaches to enhance the treatment experience for SCD patients undergoing gene therapy.

*
In June 2024, Vertex Pharmaceuticals shared long-term results for its gene therapy, Casgevy (exa-cel), in patients with sickle cell disease or transfusion-dependent beta-thalassemia (TDT).

*
In 2023, the United States held the largest market share for Sickle Cell Disease among the 6MM, with approximately USD 603 million, followed by France and the UK.

*
At present, treatments for Sickle Cell Disease include NSAIDs, blood transfusions, chelating agents, nutritional supplements, and broad-spectrum antibiotics. Additionally, the US FDA has approved several therapies for this condition, such as DROXIA (hydroxyurea), ENDARI (L-glutamine oral powder), ADAKVEO (crizanlizumab-tmca), and OXBRYTA (voxelotor).

*
In 2023, the United States had the largest total number of prevalent Sickle Cell Disease cases among the 6MM.

*
In the US, Sickle Cell Anemia (hemoglobin S/S or hemoglobin S/0-thalassemia) was the most common subtype of Sickle Cell Disease among the type-specific prevalent cases in 2023.

*
In the EU4 and the UK, France had the highest prevalence of Sickle Cell Disease cases, followed by the UK, while Spain reported the lowest number of cases.

*
Key Sickle Cell Disease Companies: BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, Alexion Pharmaceuticals, Takeda, Prolong Pharmaceuticals, Roche, Beam Therapeutics, Editas Medicine, Sangamo Therapeutics, Bellicum Pharmaceuticals, Invenux, EpiDestiny, Hillhurst Biopharmaceuticals, CSL Behring, Fulcrum Therapeutics, Sana Biotechnology, and others

*
Key Sickle Cell Disease Therapies: RL 101, ORY-300, GSK 4172239D, AG-946, BEAM-101, Nula-cel, RG 6107, Isoquercetin, Renizgamglogene autogedtemcel, Inclacumab, L-glutamine, CASGEVY, CTX001, LentiGlobin BB305, Inclacumab, Etavopivat, Mitapivat, ALXN1820, TAK-755, Sanguinate, Crovalimab, BEAM101, EDIT 301, BIVV003, BPX-501, SCD-101, Nicotinamide, HBI-002, CSL889, FTX-6058, SG418n, and others

*
The Sickle Cell Disease epidemiology based on gender analyzed that Sickle Cell Disease affects males and females equally

*
The Sickle Cell Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Sickle Cell Disease pipeline products will significantly revolutionize the Sickle Cell Disease market dynamics.

Sickle Cell Disease Overview

Sickle cell disease (SCD) comprises inherited red blood cell disorders resulting from an abnormality in the structure of hemoglobin known as sickle hemoglobin (HbS), which encodes the beta hemoglobin subunit.

Get a Free sample for the Sickle Cell Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/sickle-cell-disease-market [https://www.delveinsight.com/report-store/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sickle Cell Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Sickle Cell Disease Epidemiology Segmentation:

The Sickle Cell Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Sickle Cell Disease

*
Prevalent Cases of Sickle Cell Disease by severity

*
Gender-specific Prevalence of Sickle Cell Disease

*
Diagnosed Cases of Episodic and Chronic Sickle Cell Disease

Download the report to understand which factors are driving Sickle Cell Disease epidemiology trends @ Sickle Cell Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Sickle Cell Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sickle Cell Disease market or expected to get launched during the study period. The analysis covers Sickle Cell Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Sickle Cell Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Sickle Cell Disease Therapies and Key Companies

*
RL 101: BRL Medicine

*
ORY-300:1 Oryzon Genomics

*
GSK 4172239D: GlaxoSmithKline

*
AG-946: Agios Pharmaceuticals

*
BEAM-101: Beam Therapeutics Inc.

*
Nula-cel: Graphite Bio

*
RG 6107: Roche

*
Isoquercetin: Quercis Pharma

*
Renizgamglogene autogedtemcel: Editas Medicin

*
Inclacumab: Pfizer

*
L-glutamine: Emmaus Medical, Inc

*
CASGEVY: Vertex Pharmaceuticals

*
ESCAPE: Beam Therapeutic

*
IHP-102: IHP Therapeutics

*
HBI-002: Hillhurst Biopharmaceuticals

*
BEAM101: Beam Therapeutics

*
EPI01: Novo Nordisk

*
VIT-2763: CSL Vifor

*
Inclacumab: Pfizer

*
L-glutamine: Emmaus Medical

*
Oxbryta: Pfizer

*
Exagamglogene autotemcel: CRISPR Therapeutics/Vertex Pharmaceuticals

*
Mitapivat: Agios Pharmaceuticals

*
Canakinumab: Novartis

*
ALXN1820: Alexion Pharmaceuticals

*
Crovalimab: Chugai Pharmaceutical/Roche

*
EDIT 301: Editas Medicine

*
BIVV003: Sangamo Therapeutics

*
BEAM101: Beam Therapeutics

*
Hemopexin: CSL Behring

Discover more about therapies set to grab major Sickle Cell Disease market share @ Sickle Cell Disease Treatment Landscape [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Sickle Cell Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom)]

*
Key Sickle Cell Disease Companies: BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharmaceuticals, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis Pharma, Editas Medicin, Pfizer, Emmaus Medical, Inc, Vertex Pharmaceuticals, CRISPR therapeutics, Bluebird Bio, Pfizer, Novo Nordisk, Agios Pharmaceuticals, Alexion Pharmaceuticals, Takeda, Prolong Pharmaceuticals, Roche, Beam Therapeutics, Editas Medicine, Sangamo Therapeutics, Bellicum Pharmaceuticals, Invenux, EpiDestiny, Hillhurst Biopharmaceuticals, CSL Behring, Fulcrum Therapeutics, Sana Biotechnology, and others

*
Key Sickle Cell Disease Therapies: RL 101, ORY-300, GSK 4172239D, AG-946, BEAM-101, Nula-cel, RG 6107, Isoquercetin, Renizgamglogene autogedtemcel, Inclacumab, L-glutamine, CASGEVY, CTX001, LentiGlobin BB305, Inclacumab, Etavopivat, Mitapivat, ALXN1820, TAK-755, Sanguinate, Crovalimab, BEAM101, EDIT 301, BIVV003, BPX-501, SCD-101, Nicotinamide, HBI-002, CSL889, FTX-6058, SG418, and others

*
Sickle Cell Disease Therapeutic Assessment: Sickle Cell Disease current marketed and Sickle Cell Disease emerging therapies

*
Sickle Cell Disease Market Dynamics: Sickle Cell Disease market drivers and Sickle Cell Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Sickle Cell Disease Unmet Needs, KOL's views, Analyst's views, Sickle Cell Disease Market Access and Reimbursement

To know more about Sickle Cell Disease companies working in the treatment market, visit @ Sickle Cell Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/sickle-cell-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Sickle Cell Disease Market Report Introduction

2. Executive Summary for Sickle Cell Disease

3. SWOT analysis of Sickle Cell Disease

4. Sickle Cell Disease Patient Share (%) Overview at a Glance

5. Sickle Cell Disease Market Overview at a Glance

6. Sickle Cell Disease Disease Background and Overview

7. Sickle Cell Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Sickle Cell Disease

9. Sickle Cell Disease Current Treatment and Medical Practices

10. Sickle Cell Disease Unmet Needs

11. Sickle Cell Disease Emerging Therapies

12. Sickle Cell Disease Market Outlook

13. Country-Wise Sickle Cell Disease Market Analysis (2020-2034)

14. Sickle Cell Disease Market Access and Reimbursement of Therapies

15. Sickle Cell Disease Market Drivers

16. Sickle Cell Disease Market Barriers

17. Sickle Cell Disease Appendix

18. Sickle Cell Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=sickle-cell-disease-market-to-witness-promising-upswing-by-2034-delveinsight-forecasts-sanofi-csl-behring-itbmed-llc-novo-nordisk-as-fortrea-inc-novartis-afimmune-pfizer-addmedica-sasa]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.